Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.

Takahiro TakazonoSatoki FujitaTakuji KomedaShogo MiyazawaYuki YoshidaYoshitake KitanishiMasahiro KinoshitaSatoshi KojimaHuilian ShenTakeki UeharaNaoki HosogayaNaoki IwanagaHiroshi Mukae

Published in: Infectious diseases and therapy (2024)

The incidence of all-cause hospitalization was significantly lower in the ensitrelvir group than in the no antiviral treatment group, suggesting ensitrelvir is an effective treatment in patients at risk of severe COVID-19.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
systematic review
early onset
skeletal muscle
insulin resistance